Recommendations: Cystic Fibrosis-Related Diabetes (CFRD) (2)
Recommendations for the care of patients with cystic-fibrosis-related diabetes (CFRD)1 are summarized in two slides Slide 2 of 2 Patients with CFRD should be treated with insulin to attain individualized glycemic goals (A) Annual monitoring for complications of diabetes is recommended, beginning 5 years after the diagnosis of CFRD (E) Encouraging new data suggest early detection and aggressive insulin therapy have narrowed the gap in mortality between cystic fibrosis patients with and without diabetes, and have eliminated the sex difference in mortality2 Recommendations for the clinical management of CFRD can be found in a recent ADA position statement on this topic3131References American Diabetes Association. Standards of medical care in diabetes—2013. Diabetes Care 2013;36(suppl 1):S45. Moran A, Dunitz J, Nathan B, Saeed A, Holme B, Thomas W. Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality. Diabetes Care 2009;32:1626-1631. Moran A, Brunzell C, Cohen RC, et al. CFRD Guidelines Committee. Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care 2010;33:2697-2708.